Document is current
Any future updates will be listed below
-
Authors
Schoretsanitis, Georgios https://orcid.org/0000-0002-3851-4117
de Leon, Jose https://orcid.org/0000-0002-7756-2314
Eap, Chin B. https://orcid.org/0000-0002-5439-0230
Kane, John M. https://orcid.org/0000-0002-2628-9442
Paulzen, Michael https://orcid.org/0000-0003-4198-5160
- License Information
-
More Information
Article History
First Online: 27 November 2019
Compliance with Ethical Standards
:
: No commercial organizations had any role in writing this paper for publication.
: Dr. Kane has been a consultant for or received honoraria from Alkermes, Dainippon Sumitomo, Eli Lilly, Forum, Allergan, Genentech, H. Lundbeck, Intracellular Therapies, Janssen Pharmaceutica, Johnson and Johnson, LB Pharmaceuticals, Merck, Minerva, Neurocrine, Otsuka, Pierre Fabre, Reviva, Roche, Sunovion, Takeda and Teva. He has received grant support from Otsuka, Lundbeck and Janssen and royalties from Up to Date. He has participated in advisory boards for Alkermes, Dainippon Sumitomo, Intracellular Therapies, Lundbeck, Neurocrine, Otsuka, Pierre Fabre, Takeda, and Teva. He is a shareholder in Vanguard Research Group and LB Pharmaceuticals, Inc. Dr. Eap received honoraria for conferences or teaching CME courses from Forum für Medizinische Fortbildung, Janssen-Cilag, Lundbeck, Mepha, Otsuka, Sandoz, Servier, Sunovion, Vifor-Pharma and Zeller, a payment from Astra Zeneca in the past 3 years, and honoraria for writing a review article for the journal <i>Dialogues in Clinical Neuroscience</i> (Servier). Dr. Paulzen received a speaker's fee from Neuraxpharm. Drs. Schoretsanitis and de Leon have no conflicts of interest relating to the last 3 years.
